<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02826837</url>
  </required_header>
  <id_info>
    <org_study_id>LEAC-102-01</org_study_id>
    <nct_id>NCT02826837</nct_id>
  </id_info>
  <brief_title>LEAC-102 for Advanced Colorectal Cancer</brief_title>
  <official_title>A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination With FOLFOX + Bevacizumab/Cetuximab in Subjects With Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiwan Leader Biotech Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiwan Leader Biotech Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of
      LEAC-102 in Combination with FOLFOX + Bevacizumab/Cetuximab in Subjects with Advanced
      Colorectal Cancer
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>Week 4</time_frame>
    <description>First two cycles of FOLFOX + Bevacizumab/Cetuximab for advanced Colorectal Cancer (cycle length = 2 weeks)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidences of myelosuppression</measure>
    <time_frame>Weeks Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in white blood cells (WBCs) level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in platelet level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum inflammatory cytokines level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum c-reactive protein level at all post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in global health/QoL standardized score at post-treatment visits compared to baseline</measure>
    <time_frame>Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22,24</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>LEAC-102 and FOLFOX+Bevacizumab/Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects will be administered folinic acid (Leucovorin; LV), Fluorouracil (5-FU) and Oxaliplatin (FOLFOX) + Bevacizumab/Cetuximab by intravenous infusion.
Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.
A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day
Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab</intervention_name>
    <description>The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.
Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.
A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day
Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)</description>
    <arm_group_label>LEAC-102 and FOLFOX+Bevacizumab/Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged at least 20 years old

          2. Histologically or cytologically confirmed measurable and/or evaluable advanced (stage
             III/IV) colorectal cancer that can be accurately assessed by CT/MRI scan (RECIST v1.1)
             for which regimen of FOLFOX + Bevacizumab/Cetuximab is arranged by the investigator

          3. Subjects may be treatment naïve, or may have received therapy for colorectal cancer.

          4. ECOG performance status ≤ 2 and life expectancy ≥ 12 months Note: ECOG = Eastern
             Cooperative Oncology Group

          5. Dated and signed informed consent

        Exclusion Criteria:

          1. Primary CNS malignancies or clinically active CNS metastases Note: CNS = central
             nervous system

          2. Ascertained hypersensitivity to any component of investigational product or FOLFOX +
             Bevacizumab/Cetuximab that the subject will be treated

          3. Any of the following hematologic abnormalities:

               1. Hemoglobin &lt; 10.0 g/dL,

               2. ANC &lt; 1,500/μL,

               3. Platelets &lt; 100,000 /μL Note: ANC = absolute neutrophil count

          4. Any of the following serum chemistry abnormalities:

               1. Total bilirubin &gt; 1.5 × ULN,

               2. AST or ALT &gt; 2.5 × ULN,

               3. Gamma-GT &gt; 2.5 x ULN,

               4. Alk-P &gt; 2.5 x ULN,

               5. serum albumin &lt; 3.0 g/dL,

               6. creatinine &gt; 1.5 × ULN,

               7. any other ≥ Grade 3 laboratory abnormality at baseline (other than those listed
                  above)

             Note: ULN = upper limit of normal. AST = aspartate transaminase, ALT: alanine
             transaminase, Gamma-GT = Gamma-glutamyl transferase, Alk-P = alkaline phosphatase

          5. Requirement for ongoing systemic steroid, or immunosuppressive agents

          6. Uncontrolled nausea or vomiting or any symptom that would prevent the ability to
             comply with daily oral LEAC-102 treatment

          7. Active clinically serious infection

          8. Known history of HIV or hepatitis B or C Note: HIV = human immunodeficiency virus

          9. Uncontrolled psychiatric disorder or altered mental status precluding informed consent
             or necessary testing

         10. Consumption of herbal preparations/supplements (except for a daily
             multivitamin/mineral supplement not containing herbal components) within 2 weeks prior
             to the start of Cycle 1 of FOLFOX + Bevacizumab/Cetuximab administration

         11. Significant cardiovascular disease, including:

               1. Active clinically symptomatic left ventricular failure

               2. Active hypertension (diastolic blood pressure &gt; 100 mmHg). Subjects with a
                  history of hypertension must have been on stable doses of anti-hypertensive drugs
                  for ≥ 4 weeks prior to start of Cycle 1 of FOLFOX + Bevacizumab/Cetuximab
                  administration

               3. Uncontrolled hypertension: Blood pressure &gt;140/90 mmHg on more than 2
                  antihypertensive medications

               4. Myocardial infarction, severe angina, or unstable angina within 12 weeks prior to
                  start of Cycle 1 of FOLFOX + Bevacizumab/Cetuximab administration

               5. History of serious ventricular arrhythmia (i.e., ventricular tachycardia or
                  ventricular fibrillation)

         12. Significant gastrointestinal disorder(s) that would, in the opinion of the Principal
             Investigator, prevent absorption of an orally available agent

         13. Has received an investigational agent within 4 weeks of entering this study

         14. With any condition judged by the investigator that entering the trial may be
             detrimental to the subject

        15 Female with childbearing potential who is lactating or has positive urine pregnancy test
        at Screening visit

        16. Subject with either gender refuses to adopt at least two forms of birth control (at
        least one of which must be a barrier method) during the study and until 30 days after study
        treatment.

        Note: Acceptable forms include:

          1. Established use of oral, injected or implanted hormonal methods of contraception.

          2. Placement of an intrauterine device (IUD) or intrauterine system (IUS).

          3. Barrier methods of contraception: Condom OR Occlusive cap (diaphragm or cervical/vault
             caps) with spermicidal foam/gel/film/cream/suppository

        17. Subjects with grade 2 or above chronic neuropathy

        18. Subjects with known dihydropyrimidine dehydrogenase (DPD) deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kate Chen, Ph.D,</last_name>
    <phone>+886-2-2559-2777</phone>
    <phone_ext>609</phone_ext>
    <email>kate_chen@twleaderlife.com</email>
  </overall_contact>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2016</study_first_submitted>
  <study_first_submitted_qc>July 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2016</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

